Skip to main content

NeuroPace Inc

NPCE
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001528287

No open-market purchases or sales by NeuroPace Inc insiders were filed in the last 90 days; 112 institutions reported holding it in 13F filings for Q2 2026, worth $422.4M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding NeuroPace Inc changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of NPCE: Q2 2021 compared with Q3 2021
MeasureQ2 2021Of which not filed for Q3 2021Q3 2021Change
Holders44239−3
Shares10.9M541.4K11.2M+825.8K (+8.0%)
Value$259.5M$12.9M$177.4M−$69.2M (−28.1%)

2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held NeuroPace Inc at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to NPCE in Q3 2021
InstitutionSharesValue% of portfolio
Pictet Asset Management SA569,875$9.03M0.01%
Amundi81,157$1.29M0.00%
Johnson & Johnson55,435$879.0K0.08%
Citadel Advisors LLC25,822$410.0K0.00%

Sold out (7)

Institutions that held NeuroPace Inc at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of NPCE in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Pura Vida Investments, LLC229,264$5.45M
Avidity Partners Management LP40,000$952.0K
Caas Capital Management LP40,000$952.0K
Marshall Wace, LLP14,939$355.0K
Jane Street Group, LLC9,037$215.0K
UBS Group AG2,563$61.0K
STRS Ohio1,600$38.0K

Not filed for Q3 2021 yet (2)

Institutions that held NeuroPace Inc at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NPCE in Q2 2021 that haven't filed for Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Pictet Asset Management Ltd485,964$11.6M
Johnson & Johnson Innovation - JJDC, Inc.55,435$1.32M